pSuper Retro GFP DGK zeta mouse
(Plasmid
#224577)
-
PurposeNegative Control for downregulation of the expression of human DGK zeta in human cells
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 224577 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepSUPER Retro GFP
-
Backbone manufacturerOligoengine
- Backbone size w/o insert (bp) 8371
-
Vector typeRetroviral, RNAi
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert namesh RNAi Diacylglycerol kinase zeta mouse
-
gRNA/shRNA sequenceCTATGTGACGGAGATTGCCttcaagagaGGCAATCTCCGTCACATAG
-
SpeciesM. musculus (mouse)
-
Insert Size (bp)64
-
Entrez GeneDgkz (a.k.a. E130307B02Rik, F730209L11Rik, mDGK[z])
- Promoter H1
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site Bgl2 (destroyed during cloning)
- 3′ cloning site Hind3 (not destroyed)
- 5′ sequencing primer pSuperRetro2
- 3′ sequencing primer pSuperRetro 1 (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pSuper Retro GFP DGK zeta mouse was a gift from Isabel Mérida (Addgene plasmid # 224577 ; http://n2t.net/addgene:224577 ; RRID:Addgene_224577) -
For your References section:
Diacylglycerol kinase alpha promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src. Torres-Ayuso P, Daza-Martin M, Martin-Perez J, Avila-Flores A, Merida I. Oncotarget. 2014 Oct 30;5(20):9710-26. doi: 10.18632/oncotarget.2344. 10.18632/oncotarget.2344 PubMed 25339152